John Williams, MD
Interventional Cardiology · Oklahoma City, OKNPI 1811984719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,204 of the $15,895 with a category attached, or 64.2%. 30 manufacturers reported payments, led by Edwards Lifesciences at 33.9% of the total. Reporting peaked in 2022 at $3,638 and has fallen 80.1% since, to $724 in 2025.
Across 368 payments — averaging $43.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$5K
- Medtronic$3K
- Abbott$2K
- Amgen$964
- E.r. Squibb & Sons, L.L.C.$847
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$466
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$350%
- Travel & lodging$5,65636%
- Food & beverage$10,20464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 40 | $5,389 |
| Medtronic(2 entities) | 23 | $3,350 |
| Abbott | 39 | $1,573 |
| Amgen | 29 | $964 |
| E.r. Squibb & Sons, L.L.C. | 45 | $847 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $466 |
| AstraZeneca | 26 | $421 |
| Kowa Pharmaceuticals America, Inc. | 21 | $352 |
| Johnson & Johnson | 21 | $349 |
| Pfizer | 17 | $297 |
| Merck | 16 | $262 |
| Amarin Pharma, Inc. | 5 | $205 |
| Boehringer Ingelheim | 11 | $183 |
| Novartis | 10 | $177 |
| Novo Nordisk | 4 | $171 |
| Irhythm Technologies, Inc. | 8 | $163 |
| Regeneron Healthcare Solutions, Inc. | 3 | $133 |
| Actelion Pharmaceuticals US, Inc. | 6 | $112 |
| Boston Scientific | 3 | $73 |
| Baxter Healthcare | 1 | $58 |
| Lexicon Pharmaceuticals, Inc. | 2 | $56 |
| Atricure, Inc. | 2 | $47 |
| Bayer | 2 | $45 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Sanofi-aventis U.S. LLC | 3 | $37 |
| Medicure Pharma Inc. | 1 | $35 |
| Abiomed | 1 | $34 |
| Cashflow Solutions, LLC | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,685
- CoreValve Evolut$1,132
- CARDIOMEMS$602
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$497
- Repatha$363
- COREVALVE EVOLUT R$184
- DRAGONFLY OPSTAR$166
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$158
- CAPSUREFIX NOVUS MRI SURESCAN$141
- Micra$135
- Vascepa$125
- 3F$125
- CAMZYOS$123
- HeartMate 3 Left Ventricular Assist Device$108
How this compares
$15,895 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 822 | $843,315 |
| EntrestoSacubitril/Valsartan | 250 | $249,978 |
| XareltoRivaroxaban | 216 | $198,004 |
| Repatha SureclickEvolocumab | 86 | $77,556 |
| VascepaIcosapent Ethyl | 43 | $30,675 |
| JardianceEmpagliflozin | 28 | $29,347 |
| FarxigaDapagliflozin Propanediol | 23 | $28,671 |
| Praluent PenAlirocumab | 29 | $25,449 |
| MultaqDronedarone Hcl | 20 | $25,018 |
| Ranolazine ErRanolazine | 244 | $24,823 |
| Rosuvastatin Calcium | 698 | $13,502 |
| Pitavastatin Calcium | 52 | $12,105 |
| Metoprolol Succinate | 677 | $11,810 |
| BrilintaTicagrelor | 12 | $10,369 |
| Potassium Chloride | 557 | $9,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $297 | $843,315822 claims |
| NovartisEntresto | $177 | $249,978250 claims |
| Johnson & JohnsonXarelto | $349 | $198,004216 claims |
| AstraZenecaFarxiga, Brilinta | $421 | $39,04135 claims |
| Boehringer IngelheimJardiance | $183 | $29,34728 claims |
| Sanofi-aventis U.S. LLCMultaq | $37 | $25,01820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.